ADCs, or Antibody-Drug Conjugates, represent what many see as the future of targeted therapeutic medication. In a market where the likes of Teva have promised to cut 5,000 jobs, and Merck & Co have announced plans to cut 16,000 staff from their 80,000 strong workforce in the next two years, it is testament to the confidence the industry has in ADC biotechnology that billions is being spent to support development and manufacturing capacity across the globe, despite only three ADC treatments being approved (all by the FDA and two by the EMA) since the early 2000's. And one of these was withdrawn in 2010 due to concerning levels of toxicity in patients in clinical trials. With a market predicted to be worth $15 Billion by 2015 here is our list of some of the major investment in ADC that has appeared over the last few months from the BigPharma players.
Picture 1 of 6